TX、GX和NX方案治疗蒽环类耐药晚期三阴性乳腺癌的疗效及安全性  

Efficacy and safety of TX,GX and NX regimens in the treatment of anthracycline-resistant metastatic triple-negative breast cancer

作　　者：田美娟 王丽[2] 张佳 Tian Meijuan;Wang Li;Zhang Jia(Department of Medical Oncology and Hematology, Traditional Chinese Hospital of Baoji, Shaanxi University of Chinese Medicine Affiliated Hospital, Shaanxi Baoji 721000, China;Medical College of Xian Jiaotong University, Shaanxi Xian 710061, China;Department of Medical Oncology, the First Affiliated Hospital of Xian Jiaotong University, Shaanxi Xian 710061 , China)

机构地区：[1]陕西中医药大学附属宝鸡市中医医院肿瘤血液科,陕西宝鸡721000 [2]西安交通大学医学院,陕西西安710061 [3]西安交通大学医学院附属第一医院乳腺肿瘤外科,陕西西安710061

出　　处：《现代肿瘤医学》2019年第2期245-248,共4页Journal of Modern Oncology

摘　　要：目的:观察卡培他滨联合多西他赛(TX)或吉西他滨(GX)或长春瑞滨(NX)治疗蒽环类耐药晚期三阴性乳腺癌的疗效及安全性。方法:选择自2014年7月至2015年7月临床应用含卡培他滨方案联合化疗的共98例晚期三阴性乳腺癌患者作为研究对象,其中TX方案组34例,GX方案组34例,NX方案组30例。每2周期评价1次疗效,观察并比较三组患者的近期疗效、疾病进展时间和不良反应。结果:每例患者均接受4～8周期化疗,全组患者共接受5 8 1次化疗。TX方案CBR为79. 4%,中位TTP 9. 1个月; GX方案CBR为73. 5%,中位TTP 8. 7个月; NX方案CBR为73. 3%,中位TTP 8. 5个月。主要不良反应均可耐受。结论:对于蒽环类耐药晚期三阴性乳腺癌,以卡培他滨为基础的联合化疗可提高疾病缓解率、延长疾病进展时间,患者耐受性好,是不能耐受两药或三药联合静脉化疗患者的较好选择。Objective:To investigate the efficacy and safety of capecitabine plus docetaxel(TX)or gemcitabine(GX)or vinorelbine(NX)chemotherapy in patients with anthracycline-resistant metastatic triple-negative breast cancer(mTNBC).Methods:98mTNBC patients treated with capecitabine-based combination chemotherapy between July2014and July2015were retrospectively analyzed,TX group of34patients,GX group of34patients,while NX group of30patients.The clinical response was evaluated every two cycles,we observed and compared the therapeutic efficacy,the time to progression(TTP)and safety of the three groups.Results:98patients received a range of4-8cycles of a capecitabine maintenance therapy,overall581cycles.In group of TX,the CBR was79.4%,and the median TTP was9.1months.For the group of GX,the CBR was73.5%,the median TTP was8.7months.For NX,the CBR was73.3%,the median TTP was8.5months.The major toxicities were tolerable.Conclusion:Capecitabine-based combination therapy can prolong time to progression and improve the disease remission rate of patients with a favorable safety profile in anthracycline-resistant TNBC patients,it s a better selection for the intolerant patients with multidrug combined venous chemotherapy.

关 键 词：三阴性乳腺癌 化疗耐受性 卡培他滨 抗肿瘤联合化疗 

分 类 号：R737.9[医药卫生—肿瘤]